Outcome Predictors in Progressive Multifocal Leukoencephalopathy Associated With Multiple Sclerosis Treatments: A Multicenter Cohort Study
Year: 2026
Type: article
Study design: Observational Study
Abstract: BACKGROUND AND OBJECTIVES: JC virus (JCV) reactivation causing progressive multifocal leukoencephalopathy (PML) is a complication in patients with multiple sclerosis (MS) treated with disease-modifying therapies (DMTs). Although natalizumab (NTZ) is most frequently involved, PML also occurs less commonly with sphingosine-1-phosphate receptor modulators (S1P-RM), dimethyl fumarate (DMF), and ocrelizumab. This study aimed to identify factors predicting worse outcomes, focusing on the influence of PML-immune reconstitution inflammatory syndrome (PML-IRIS), plasma exchange (PlEx), corticosteroids, and DMT reintroduction. METHODS: This retrospective multicenter cohort study analyzed patients with MS who had JCV-associated pathology (PML or granule cell neuronopathy) from 42 centers (2009-2022). The primary outcome was disability at 12 months, measured by the modified Rankin Scale (mRS). Multivariable analyses identified predictors of poor outcomes, PML-IRIS development, and recurrent MS activity. RESULTS: = 0.025). PlEx and corticosteroid use had no negative effect. DISCUSSION: This study provides valuable insights into the management of iatrogenic PML in patients with MS. The findings may guide clinicians in making informed decisions, particularly regarding the use of PlEx, corticosteroids, and the management of PML-IRIS.
Authors: Julie Céline Blant, Nicola De Rossi, Ralf Gold, Aude Maurousset, Markus Kraemer, Lucía Romero-Pinel, Tatsuro Misu, Jean-Christophe Ouallet, Maud Pallix Guyot, Simonetta Gerevini, Christos Bakirtzis, Raquel Piñar Morales, Benjamin Vlad, Panajotis Karypidis, Xavier Moisset, Tobias J. Derfuss, Ilijas Jelcic, Guillaume Martin-Blondel, Ilya Ayzenberg, Corey McGraw, David Axel Laplaud, Christine Lebrun-Frenay, Renaud A. Du Pasquier, Raphael Bernard-Valnet, for the CORPUS and Italian PML study groups
Institutions: Centre Hospitalier Universitaire Vaudois, University of Lausanne, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, St. Josef-Hospital, Ruhr University Bochum, Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, Alfried Krupp von Bohlen und Halbach Foundation, Alfried Krupp Hospital, Heinrich Heine University Düsseldorf, Bellvitge University Hospital, Institut d'Investigació Biomédica de Bellvitge, Tohoku University Hospital, Centre Hospitalier Universitaire de Bordeaux, Hôpital Pellegrin, Centre hospitalier universitaire d'Orléans, Ospedale Papa Giovanni XXIII, Aristotle University of Thessaloniki, University of Zurich, University Hospital Zurich, University of Basel, University Hospital of Basel, Inserm, Université Clermont Auvergne, Physiopathologie et pharmacologie de la douleur et de la migraine, Centre Hospitalier Universitaire de Clermont-Ferrand, Centre Hospitalier Universitaire de Toulouse, SUNY Upstate Medical University, Centre Hospitalier Universitaire de Nantes, Centre d'Investigation Clinique de Nantes, Center for Research in Transplantation and Translational Immunology, Université de Nantes, Nantes Université, Unité de Recherche Clinique Côte d'Azur, University Hospital Münster
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,450
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Sanofi, Biogen, Teva Pharmaceutical Industries, Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Celgene, Fondation pour l'Aide à la Recherche sur la Sclérose en Plaques, CSL Behring, Agence Nationale de la Recherche, Eisai, Genesis Pharma, Teijin Pharma, H. Lundbeck A/S, Neuraxpharm, Allergan, Novartis Pharma, Chugai Pharmaceutical, Sanofi Genzyme, Cilag
OpenAlex ID: W7130700007
